No Wegovy Shortage in Denmark Amid High Demand, Novo Nordisk Confirms
No Wegovy Shortage in Denmark Amid High Demand, Novo Nordisk Confirms
Novo Nordisk A/S (NYSE:NVO) says that despite earlier warnings from the Danish Medicines Agency about potential shortages of Wegovy, it does not anticipate a shortage of its weight-loss drug in Denmark.
Novo Nordisk A/S(纽约证券交易所代码:NVO)表示,尽管丹麦药品管理局早些时候曾警告说Wegovy可能出现短缺,但预计其减肥药物在丹麦不会短缺。
The agency had warned of limited supply for the 1 mg injection pen from late May to mid-June and the 0.5 mg injection pen from mid-June to mid-July due to increased demand.
该机构曾警告说,由于需求增加,从5月下旬到6月中旬,1毫克注射笔的供应有限,从6月中旬到7月中旬,0.5毫克注射笔的供应有限。
Also Read: What Are Pricing Strategies for Ozempic And Wegovy With Potential Medicare Coverage Expansion? Senate Committee Questions Novo Nordisk.
另请阅读: 可能扩大医疗保险覆盖范围的Ozempic和Wegovy的定价策略是什么?参议院委员会质疑诺和诺德。
In both cases, the expected shortage was due to rising demand, the medicines agency said.
该药品机构表示,在这两种情况下,预期的短缺都是由于需求增加造成的。
"Novo Nordisk is experiencing a high demand for Wegovy, which can result in periodic backorders of various doses of the product in Denmark," Novo Nordisk said in a statement to Reuters.
诺和诺德在给路透社的一份声明中说:“诺和诺德对Wegovy的需求很高,这可能导致丹麦定期缺货各种剂量的该产品。”
"In the case of Wegovy FlexTouch 1.0 mg and 0.5 mg, the announcements from the Danish Medicines Agency are no longer current," it said.
它说:“就Wegovy FlexTouch1.0毫克和0.5毫克而言,丹麦药品管理局的公告已不再是最新的。”
Wegovy is given by weekly injection. It starts at 0.25 mg of the active ingredient semaglutide and gradually increases to a maintenance dose of 2.4 mg.
Wegovy 每周注射一次。它从活性成分索玛鲁肽的0.25 mg开始,然后逐渐增加到2.4 mg的维持剂量。
Novo, struggling with supply constraints due to run-away demand for the hugely popular drug, said all doses were available in Denmark.
由于对这种广受欢迎的药物的需求失控,Novo在供应限制中苦苦挣扎。Novo表示,所有剂量均可在丹麦上市。
Earlier this month, as per a media report, online pharmacies and slimming clinics in Britain are reducing prices for Novo Nordisk's Wegvoy and Eli Lilly And Co's (NYSE:LLY) Mounjaro as initial supply shortages ease, a move driven by growing competition among retailers.
据媒体报道,本月早些时候,随着初始供应短缺的缓解,英国的在线药房和减肥诊所正在降低诺和诺德旗下的Wegvoy和Eli Lilly And Co(纽约证券交易所代码:LLY)Mounjaro的价格,此举是由零售商之间日益激烈的竞争所推动的。
In April, Novo Nordisk warned that starter kits for its widely used diabetes drug Ozempic (semaglutide) would not be available in Germany during the second quarter.
4月,诺和诺德警告说,其广泛使用的糖尿病药物Ozempic(索马鲁肽)的入门套件将在第二季度在德国上市。
Price Action: NVO shares are up 0.82% at $134.01 at last check Wednesday.
价格走势:周三最后一次检查时,NVO股价上涨0.82%,至134.01美元。
Image Via Shutterstock
图片来自 Shutterstock